Mesoblast was established in 2004 to develop therapies for patients with bone and joint diseases, and has acquired the worldwide licence to commercialise orthopaedic applications of proprietary adult stem cell technology developed by scientists at South Australia's Hanson Institute and Institute of Medical and Veterinary Science (IMVS).
|
|
The technology is based on precise identification and efficient isolation of a population of adult stem cells called mesenchymal precursor cells (MPC), which are found at various sites throughout the body, and which have the ability to transform into bone, cartilage, fat, and other tissues.
The cells can also create new blood vessel networks and secrete molecules that 'tell' the body's own tissues to regrow into regions damaged by disease. MPC are capable of both limiting the extent of the injury and increasing the repair of the injured area. |
When tissue injury persists, the body's own supply of MPC is unable to deal with the problem unassisted. Mesoblast's approach is to deliver large numbers of MPC to the injured site, providing the body with the means to fix itself by using the complex, natural pathways available to MPC.
Mesoblast has achieved outstanding clinical and preclinical results, demonstrating union of non-healing long bone defects. For more information, please see: http://www.mesoblast.com/mediareleases/news_mediareleases89.pdf
Mesoblast has also acquired a 39.2% interest in Angioblast Systems, Inc., which is commercialising the MPC technology for cardiac, vascular, and eye conditions.
Mesoblast is forming strategic corporate alliances with major industry players with market leadership positions who may be seeking pipeline extension or other competitive advantage in their markets. From these strategic corporate alliances, Mesoblast expects to potentially earn significant immediate, short-term and/or mid-term milestone payments. In the longer term, Mesoblast expects to earn significant royalty revenue from the successful sale of its MPC products.
About us
Organisation
Executive management
Scientific Advisory Board
Corporate Governance
|
